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Cancer nanotherapeutics are progressing rapidly with innovative drug delivery systems to 
replace conventional delivery systems. Although, antitumor activity of zerumbone (ZER) 
has been reported, there has been no available information of ZER-loaded nanostructured 
lipid carrier (NLC) affects murine leukemia cells in vivo. In a previous study, ZER was 
incorporated into NLC by high pressure homogenization (HPH) technique. 
Physicochemical characterization included particle size, polydipersity index, zeta potential, 
pH, entrapment efficiency, loading capacity, stability study, and in vitro drug release, as 
well as physicochemical stability after being autoclaved and stored at 4˚C, 25˚C and 40˚C 
for 1 month, were examined. In this study, in vivo effects of ZER-NLC on murine 
leukemia WEHI-3B cells were investigated. The outcomes of histopathology, TEM and 
TUNEL assays of BALB/c leukemia mice revealed that the number of leukemia cells were 
significantly (P < 0.05) decreased in spleen tissue after four weeks of oral administration 
of ZER-NLC. In conclusion, NLC is suggested as a promising carrier for ZER oral 
delivery. 
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